bersacapavir (JNJ-56136379) / J&J 
Welcome,         Profile    Billing    Logout  
 0 Diseases   2 Trials   2 Trials   13 News 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bersacapavir (JNJ-56136379) / J&J
NCT04288310 / 2019-002674-31: A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

Recruiting
2b
120
Europe
JNJ-73763989, JNJ-56136379, Placebo for JNJ-73763989, Placebo for JNJ-56136379, Entecavir (ETV) monohydrate, Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide (TAF)
Janssen Sciences Ireland UC
Hepatitis B, Chronic
01/22
02/22
2019-004978-26: A clinical study to evaluate efficacy, pharmacokinetics, safety, and tolerability of response-guided treatment with JNJ-73763989 + JNJ-56136379 + nucleos(t)ide analog regimen with or without pegylated interferon alpha-2a in treatment-naïve patients with HBeAg positive chronic hepatitis B virus infection.

Not yet recruiting
2
80
Europe
JNJ-73763989, JNJ-56136379, Solution for injection, Tablet, Film-coated tablet, Solution for injection in pre-filled syringe, Tenofovir disoproxil Mylan 245 mg film-coated tablets, Vemlidy 25 mg film-coated tablets, Pegasys 180 micrograms solution for injection in pre-filled syringe
Janssen-Cilag International NV, Janssen Sciences Ireland Unlimited Company
Chronic Hepatitis B Virus Infection, Chronic Hepatitis B Virus Infection, Diseases [C] - Virus Diseases [C02]
 
 
2019-000622-22: A Clinical Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

Not yet recruiting
2
450
Europe
JNJ-56136379, JNJ-73763989, Solution for injection, Tablet, Film-coated tablet, Baraclude, Viread, Vemlidy
Janssen Sciences Ireland UC, Janssen Sciences Ireland Unlimited Company, Janssen Sciences Ireland UC, Janssen Sciences Ireland Unlimited Company, Janssen Cilag S.p.A.
Chronic Hepatitis B Virus Infection, Chronic Hepatitis B Virus Infection, Diseases [C] - Virus Diseases [C02]
 
 
PENGUIN, NCT04667104: A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

Completed
2
48
Europe, Japan, RoW
JNJ-73763989, JNJ-3989, Tenofovir disoproxil, Tenofovir alafenamide (TAF), Entecavir (ETV) monohydrate, PegIFN-alpha2a
Janssen Research & Development, LLC
Hepatitis B, Chronic
05/22
04/23
INSIGHT, NCT04585789 / 2019-004475-39: A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection

Completed
2
24
Europe, Canada, US, RoW
JNJ-73763989, JNJ-56136379, Entecavir (ETV), Tenofovir disoproxil, Tenofovir alafenamide (TAF), PegIFN-alpha-2a (Optional)
Janssen Research & Development, LLC
Hepatitis B
02/23
01/24
2020-003956-34: A Clinical Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Treatment With JNJ-73763989, JNJ-56136379, Nucleos(t)ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection.

Not yet recruiting
2
50
Europe
JNJ-73763989, Solution for injection, Film-coated tablet, Solution for injection in pre-filled syringe, Viread 245 mg film-coated tablets, Vemlidy 25 mg film-coated tablets, Entecavir Mylan 0.5 mg film-coated tablets, Pegasys 180 micrograms solution for injection in pre-filled syringe
Janssen-Cilag International NV, Janssen Research and Development LLC
Chronic Hepatitis B Virus Infection, Chronic Hepatitis B Virus Infection, Diseases [C] - Virus Diseases [C02]
 
 
NCT04439539: A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

Completed
2
54
Europe, Canada, Japan, US, RoW
JNJ-73763989, JNJ-3989, PegIFN-alpha-2a, Tenofovir disoproxil, Tenofovir alafenamide, JNJ-56136379, JNJ-6379
Janssen Research & Development, LLC
Hepatitis B, Chronic
08/23
02/24

Download Options